Clinical Observation Of Buqihuajifang In The Treatment Of Chronic Atrophic Gastritis With Qi Deficiency And Blood Stasis

ObjectiveBy observing the changes of gastroscope index,pathology score and TCM syndrome score before and after the treatment of "Buqihuajifang" in the treatment of chronic atrophic gastritis with qi deficiency and blood stasis,the efficacy and safety were evaluated.MethodsThis research adopts the randomized controlled research method.69 patients who met the inclusion criteria were randomly divided into the observation group(35 cases)and the control group(34 cases).The observation group was treated with Buqihuajifang(1 dose per day,2oral treatments per day),while the control group was treated with weifuchun tablets(4 tablets per day,3 oral treatments per day).The treatment courses of both groups were 12 weeks.The changes of gastroscopy index,histopathological score,TCM symptom score before and after treatment were observed to evaluate its effectiveness.Blood,urine,fecal routine,liver and kidney function,ecg were used as safety indicators to evaluate its safety in combination with adverse reactions.Results1.In this study,1 person was excluded and 69 people were included.Four people were droped from the observation group.Finally,65 cases were successfully collected,34 in the control group and 31 in the observation group.The dropout rate is 5.71%.2.Before the treatment,there was no statistical significance in the comparison of gender,age,course of disease,gastroscope score,pathology score and TCM symptom score between the two groups(P>0.05).3.Comparison of efficacy of gastroscopy: the total effective rate of gastroscopy in the observation group was 93.45%,and that in the control group was 70.59%.There was a significant difference between the two groups(P<0.01).4.Comparison of pathological efficacy: in terms of chronic inflammation,atrophy and intestinal metaplasia,there was a statistically significant difference between the two groups before and after treatment,and a statistically significant difference between the observation group and the control group after treatment(P<0.05).In terms of activity and dysplasia,there was no statistically significant difference between the two groups before and after treatment(P>0.05).5.Comparison of TCM syndrome score and single score: the difference of TCM syndrome score and single score between the two groups before and after treatment was statistically significant(P<0.01),and the difference between the observation group and the control group after treatment was statistically significant(P<0.05).6.Comparison of TCM syndrome efficacy: the total effective rate was 90.32% in the observation group and 76.47% in the control group,and the difference between the two groups was statistically significant(P<0.01).7.No adverse events occurred during the treatment,and no significant abnormal changes were observed in the safety indexes of ecg,liver and kidney function before and after treatment.Conclusion1.Buqihuajifang can effectively improve the clinical symptoms,gastroscopic signs and pathological status of patients with chronic atrophic gastritis.2.Buqihuajifang shows no obvious untoward effective,and actually proves to be favorably safe.